infect
signific
caus
morbid
mortal
kidney
transplant
implic
allograft
dysfunct
reject
loss
opportunist
tradit
organ
import
caus
infect
risk
specif
infect
vari
time
posttranspl
exposur
degre
immunosuppress
array
pathogen
divers
risk
factor
necessarili
modifi
caus
exposur
consist
anticip
prevent
infect
complic
imperfect
process
moreov
clinic
present
infect
may
atyp
set
immunosuppress
make
diagnosi
difficult
concurr
coinfect
multipl
organ
occur
case
difficult
differenti
infecti
noninfecti
caus
patient
present
transplant
recipi
chronic
maintain
immunosuppress
especi
risk
sever
present
infect
even
organ
tradit
associ
benign
cours
prompt
accur
diagnosi
imper
ensur
optim
outcom
infect
kidney
transplant
recipi
view
balanc
host
interact
environ
mediat
prophylact
strategi
transplant
recipi
may
underli
condit
associ
depress
host
immun
administr
exogen
immunosuppress
requir
maintain
allograft
function
choic
immunosuppress
play
import
role
specif
infect
risk
exampl
tcell
deplet
therapi
includ
antithymocyt
globulin
increas
risk
opportunist
infect
mammalian
target
rapamycin
mtor
inhibitor
associ
skin
soft
tissu
infect
tabl
risk
infect
also
reflect
recipi
exposur
includ
pretranspl
infect
potenti
latenc
eg
herpesviru
infect
tuberculosi
tb
well
infect
associ
transplant
includ
donorderiv
hospitalacquir
infect
posttranspl
set
new
exposur
relat
environment
commun
interact
need
consid
case
exposur
anticip
base
predict
risk
period
posttranspl
appropri
prophylaxi
administ
highest
risk
period
reduc
risk
infect
antivir
direct
cytomegaloviru
cmv
exampl
risk
mitig
thorough
evalu
potenti
recipi
donor
critic
manag
infect
risk
potenti
transplant
candid
undergo
screen
identifi
activ
infect
may
effect
transplant
elig
latent
infect
may
reactiv
transplant
affect
patient
outcom
tabl
screen
process
includ
thorough
histori
prior
infect
environment
exposur
associ
infect
risk
includ
current
prior
locat
resid
occup
hobbi
pet
close
contact
communic
diseas
tb
care
physic
examin
perform
laboratori
test
includ
serolog
test
herpesvirus
cmv
herp
simplex
viru
varicella
zoster
viru
epsteinbarr
viru
ebv
human
immunodefici
viru
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
syphili
toxoplasma
gondii
situat
window
period
infect
hiv
hbv
hcv
may
suspect
concern
regard
underli
immunodefici
may
reduc
sensit
serolog
test
nucleic
acid
antibodi
test
obtain
tuberculin
test
especi
import
either
interferon
gamma
releas
assay
igra
intraderm
tuberculin
purifi
protein
patient
histori
birth
prolong
resid
place
increas
risk
geograph
associ
infect
eg
strongyloidiasi
chaga
diseas
coccidioidomycosi
histoplasmosi
addit
serolog
test
specif
organ
consid
pretranspl
evalu
immun
histori
review
vaccin
updat
appropri
see
immun
section
tabl
donorderiv
infect
occur
rare
nevertheless
live
deceas
organ
donor
implic
donorderiv
infect
transmiss
pathogen
divers
includ
bacteria
eg
pyogen
organ
mycobacterium
tuberculosi
fungi
especi
endem
mycos
candida
virus
commonli
herpesvirus
parasit
organ
includ
strongyloid
standard
evalu
includ
thorough
histori
past
infect
exposur
associ
transmiss
infect
deceas
donor
histori
provid
surrog
gener
less
detail
howev
increas
use
pair
kidney
exchang
led
increas
number
evalu
obtain
outsid
recipi
center
whether
impact
qualiti
donor
inform
unknown
case
laboratori
test
mirror
transplant
candid
specif
attent
activ
infect
time
deceas
donat
infect
may
reactiv
immunosuppress
transplant
recipi
includ
herpesvirus
endem
mycos
parasit
infect
live
deceas
donor
see
tabl
live
donor
may
evalu
latent
tb
use
either
intraderm
tuberculin
ppd
test
igra
given
limit
tb
test
set
deceas
donor
evalu
especi
import
obtain
histor
inform
radiographi
assess
potenti
deceas
donor
latent
infect
presenc
potenti
transmiss
donor
infect
may
exclud
donor
transplant
donor
bacteremia
mening
bacteri
infect
involv
kidney
success
use
may
consid
assum
donor
appropri
treat
hour
accept
antimicrobi
treatment
option
latent
infect
donor
includ
tb
endem
mycos
may
treat
appropri
antimicrobi
transplant
donor
activ
infect
organ
effect
treatment
option
exclud
special
attent
paid
deceas
donor
undiagnos
central
nervou
system
cn
process
donor
implic
sever
fatal
donorderiv
infect
includ
west
nile
viru
rabi
cryptococcu
consequ
risk
associ
use
donor
must
balanc
need
transplant
recent
public
focus
donor
pose
increas
risk
bloodborn
viral
diseas
transmiss
behavior
associ
recent
acquisit
hiv
hcv
tabl
depend
screen
methodolog
use
serolog
vs
nucleic
acid
test
window
variabl
durat
infect
may
present
yet
detect
public
health
servic
ph
increas
risk
donor
ird
criteria
attempt
identifi
donor
risk
window
period
infect
diseas
transmiss
absolut
risk
diseas
transmiss
overal
quit
small
vari
base
risk
behavior
infect
question
test
methodolog
exampl
risk
hiv
transmiss
donor
incarcer
neg
nucleic
acid
test
nat
antibodi
test
per
risk
hcv
infect
donor
activ
intraven
iv
drug
abus
antibodi
test
alon
per
preval
ph
ird
increas
iv
drug
user
repres
largest
proport
group
donor
compar
deceas
donor
overal
ph
ird
like
young
male
less
like
meet
expand
donor
criteria
despit
better
organ
qualiti
afford
donor
organ
like
discard
odd
ratio
confid
interv
ci
howev
recipi
accept
organ
outcom
equival
observ
nonph
ird
updat
guidelin
organ
procur
transplant
network
polici
requir
nat
test
ird
well
specifi
test
live
donor
perform
within
day
transplant
surgeri
also
greater
emphasi
place
inform
consent
process
recipi
clarif
regard
assay
interv
posttranspl
test
recipi
ph
ird
serolog
nat
test
hiv
hbv
hcv
perform
month
transplant
test
hbv
year
opioid
epidem
continu
affect
larg
part
unit
state
ph
ird
continu
contribut
substanti
number
organ
donor
pool
import
patient
counsel
accept
posttranspl
outcom
well
infecti
risk
associ
organ
offer
compar
risk
death
diseas
transmiss
dialysi
recognit
high
preval
hcv
infect
among
popul
endstag
renal
diseas
esrd
hemodialysi
patient
consid
ph
ird
shown
patient
consid
organ
offer
one
studi
younger
donor
age
exposur
dialysi
longer
wait
time
organ
associ
increas
accept
ph
ird
infect
risk
may
anticip
base
net
state
immunosuppress
patient
exposur
defin
activ
latent
infect
donor
recipi
healthcar
commun
environment
person
contact
prophylact
measur
fig
standard
immunosuppress
protocol
allow
develop
timelin
anticip
infect
provid
start
point
infect
assess
tabl
infect
transplant
patient
may
sever
especi
period
intens
immunosuppress
also
may
difficult
recogn
due
absenc
typic
featur
infect
eg
fever
patient
immunosuppress
agent
noninfecti
syndrom
occasion
mimic
infect
consequ
timelin
regard
start
point
individu
patient
circumst
care
consid
determin
optim
patient
evalu
although
immunosuppress
therapi
initi
maxim
dose
time
transplant
earli
posttranspl
period
notabl
hospitalacquir
infect
especi
relat
surgic
procedur
use
devic
disrupt
host
mucocutan
barrier
includ
iv
urinari
tract
cathet
bacteri
infect
common
given
antibiot
exposur
preand
peritranspl
period
multidrugresist
organ
clostridium
difficil
increasingli
implic
recent
year
donorderiv
bacteri
infect
due
pyogen
organ
rare
typic
also
occur
first
month
fungal
infect
less
frequent
note
candida
speci
occur
frequent
usual
relat
devic
less
commonli
donor
sourc
earli
viral
infect
includ
reactiv
herp
simplex
nosocomi
transmiss
season
respiratori
virus
noroviru
rare
donorderiv
viral
infect
west
nile
viru
rabi
lymphocyt
choriomening
viru
especi
unusu
see
parasit
infect
first
month
rare
case
donorderiv
infect
includ
balamuthia
microsporida
report
intermedi
period
posttranspl
typic
consid
highest
risk
period
occurr
opportunist
infect
time
effect
exogen
immunosuppress
requir
prevent
reject
maxim
enhanc
net
state
immunosuppress
immun
modul
may
occur
set
coinfect
immunomodul
virus
cmv
relat
metabol
derang
especi
diabet
common
period
reactiv
latent
infect
acquisit
new
infect
environ
individu
donor
may
occur
result
infect
may
sever
immunosuppress
host
pathogen
seen
intermedi
period
divers
absenc
prophylaxi
includ
bacteria
eg
nocardia
speci
listeria
monocytogen
mycobacteria
especi
tb
fungi
eg
aspergillu
speci
cryptococcu
pneumocysti
jirovecii
virus
eg
cmv
ebv
parasitesprotozoa
eg
toxoplasmosi
infect
geograph
restrict
pathogen
includ
strongyloid
stercorali
trypanosoma
cruzi
endem
mycos
coccidioid
immiti
blastomyc
dermatitidi
histoplasmosi
capsulatum
also
may
occur
import
recogn
exposur
transplant
may
result
infect
period
infect
may
predict
anticip
sever
common
opportunist
infect
may
prevent
administr
prophylact
antimicrobi
tabl
use
trimethoprim
sulfamethoxazol
prevent
pneumocysti
jirovecii
pneumonia
valganciclovir
prevent
cmv
exampl
success
prophylact
strategi
howev
prophylact
antimicrobi
may
complet
erad
risk
infect
case
onset
diseas
mere
delay
prophylaxi
discontinu
chang
natur
immunosuppress
strategi
treatment
reject
also
may
affect
time
present
common
opportunist
infect
consequ
risk
period
opportunist
infect
may
extend
beyond
intermedi
risk
period
stabl
recipi
time
frame
beyond
first
month
typic
period
stabl
allograft
function
infect
less
frequent
note
occur
typic
commun
acquir
infect
caus
typic
commun
acquir
bacteri
viral
infect
urinari
tract
infect
uti
especi
common
typic
caus
enterobacteriacea
especi
escherichia
coli
respiratori
tract
infect
also
occur
often
due
communityacquir
virus
influenza
parainfluenza
respiratori
syncyti
viru
adenoviru
human
metapneumovirus
may
sever
prolong
viral
shed
increas
risk
lower
tract
diseas
morbid
allograft
reject
bacteri
pathogen
includ
legionella
pneumococcu
also
occur
transplant
patient
greater
risk
invas
pneumococc
diseas
gener
popul
although
late
period
consid
highrisk
period
opportunist
infect
may
occur
augment
immunosuppress
import
recogn
net
state
immunosuppress
estim
sole
consid
specif
medic
dose
level
patient
respons
may
vari
consider
moreov
episod
later
reject
requir
addit
augment
immunosuppress
diabet
mellitu
infect
malign
may
increas
risk
later
opportunist
infect
one
common
lateonset
opportunist
cmv
usual
occur
follow
suspens
prophylaxi
especi
cmvseroneg
recipi
cmvseroposit
donor
organ
reactiv
latent
infect
whose
control
depend
normal
tcell
function
may
occur
period
exampl
histoplasmosi
tb
report
risk
tb
higher
transplant
recipi
gener
popul
late
period
also
notabl
occurr
healthcareassoci
infect
transplant
patient
increas
risk
comorbid
malign
diabet
mellitu
vascular
diseas
condit
often
requir
addit
intervent
healthcar
facil
led
infect
hospitalacquir
pathogen
includ
multidrugresist
bacteria
clostridium
difficil
diabet
foot
infect
also
may
seen
recognit
infect
posttranspl
period
requir
consider
specif
recipi
donor
exposur
net
state
immunosuppress
comorbid
time
infect
list
potenti
pathogen
divers
diagnos
may
obscur
set
immunosuppress
broadspectrum
empir
antimicrobi
therapi
concurr
detail
evalu
involv
laboratori
radiograph
evalu
may
necessari
prevent
bad
outcom
provid
indepth
inform
regard
common
infect
encount
kidney
transplant
cmv
common
opportunist
pathogen
kidney
transplant
notabl
direct
indirect
effect
typic
occur
month
posttranspl
prophylact
antivir
administ
prophylact
antivir
use
onset
infect
delay
antivir
suspend
postprophylaxi
cmv
may
occur
posttranspl
month
rare
onset
cmv
delay
late
onset
occur
beyond
least
month
cessat
prophylaxi
later
infect
differenti
occur
shortli
suspens
prophylaxi
later
acquisit
wors
allograft
function
higher
mortal
absenc
associ
cmv
donorposit
recipientneg
dr
serostatu
manifest
cmv
divers
common
direct
effect
asymptomat
viremia
cmv
syndrom
includ
fever
malais
cytopenia
usual
leukopenia
andor
thrombocytopenia
gastrointestin
gi
symptom
includ
anorexia
diarrhea
abdomin
pain
bleed
ulcer
perfor
dissemin
infect
hepat
pneumon
pancreat
nephriti
occur
less
frequent
chorioretin
rare
late
manifest
special
concern
indirect
manifest
cmv
relat
impact
host
immun
system
decreas
allograft
patient
surviv
increas
risk
reject
increas
risk
opportunist
infect
includ
fungal
infect
posttranspl
lymphoprolif
diseas
ptld
bacteremia
note
although
associ
cmv
reject
allograft
damag
recogn
year
exact
mechan
known
possibl
mechan
includ
upregul
inflammatori
respons
alter
express
cytokin
proinflammatori
growth
factor
chemokin
increas
proinflammatori
adhes
molecul
increas
antigen
process
present
associ
major
histocompat
complex
mhc
alter
tcell
subset
composit
smooth
muscl
prolifer
induct
intracellular
reactiv
oxygen
speci
increas
procoagul
activ
note
notabl
administr
antivir
prophylaxi
cmvseroneg
recipi
cmvseroposit
organ
associ
reduct
organ
reject
improv
patient
allograft
surviv
year
observ
provid
support
critic
role
play
cmv
respect
allograft
function
pattern
transmiss
cmv
may
occur
result
primari
infect
reactiv
latent
infect
superinfect
primari
infect
occur
frequent
cmvseroneg
recipi
receiv
cmvseroposit
donor
kidney
clinic
appar
infect
approxim
recipi
absenc
prophylaxi
infrequ
primari
infect
result
blood
transfus
closeintim
contact
individu
shed
cmv
secret
commun
acquir
recipi
primari
infect
due
organ
transplant
like
experi
cmv
shortli
cessat
prophylaxi
recogn
earli
infect
may
limit
symptom
viremia
common
manifest
communityacquir
cmv
may
occur
time
transplant
often
unanticip
may
sever
sinc
major
adult
cmv
seroposit
time
transplant
mode
acquisit
common
pediatr
set
reactiv
latentrecipi
cmv
less
common
rate
vari
base
choic
immunosuppress
induct
antilymphocyt
therapi
associ
higher
incid
cmv
multipl
genotyp
cmv
gb
common
superinfect
typic
occur
donor
recipi
cmv
posit
cmv
genotyp
typic
perform
true
incid
cmv
superinfect
known
howev
cmv
occur
commonli
dr
recipi
dr
recipi
like
donor
strain
caus
agent
major
infect
mhcrestrict
virusspecif
cytotox
lymphocyt
play
major
role
control
cmv
consequ
immunosuppress
agent
interfer
host
respons
increas
risk
cmv
specif
use
antilymphocyt
antibodi
frequent
compon
induct
therapi
ablat
lymphocyt
function
prolong
period
prompt
elabor
proinflammatori
cytokin
associ
cmv
allow
reactiv
latent
viru
enhanc
viral
replic
viral
reactiv
may
promot
azathioprin
mycophenol
cyclophosphamid
although
calcineurin
inhibitor
cni
driver
reactiv
allow
amplif
reactiv
viru
tacrolimu
potent
cyclosporin
use
mtor
inhibitor
may
reduc
risk
reactiv
addit
net
state
immunosuppress
defin
choic
immunosuppress
risk
factor
develop
cmv
includ
cmvseroposit
donor
especi
recipi
cmv
seroneg
allograft
reject
coinfect
virus
hhv
host
factor
includ
genet
factor
sever
hypogammaglobulinemia
recent
assay
design
assess
cellmedi
immun
cmi
respons
use
assess
risk
cmv
one
exampl
quantiferoncmv
assay
assess
cellmedi
immun
measur
interferon
ifn
gamma
level
produc
cell
follow
vitro
stimul
cmv
antigen
individu
reduc
respons
cmv
stimul
greater
risk
cmv
fail
respond
stimul
highest
risk
allograft
reject
cmv
uniqu
bidirect
interact
wherebi
proinflammatori
environ
creat
reject
addit
treatment
immunosuppress
agent
prompt
reactiv
amplif
cmv
cmv
upregul
antigen
promot
alloreact
lead
acut
chronic
reject
syndrom
diagnosi
prompt
recognit
cmv
imper
prevent
complic
improv
outcom
requir
initi
consider
base
clinic
present
risk
assess
recipi
present
unexplain
cytopenia
gi
complaint
assess
cmv
especi
risk
factor
recent
suspend
prophylaxi
current
assay
target
detect
viremia
commonli
use
diagnosi
particular
nat
use
polymeras
chain
reaction
pcr
technolog
measur
cmv
dna
plasma
rapidli
accur
determin
presenc
cmv
blood
assay
quantifi
higher
valu
typic
correl
sever
diseas
also
use
follow
cours
treatment
effect
treatment
accompani
resolut
viremia
nat
notabl
interlaboratori
variabl
develop
intern
standard
reduc
variabl
regardless
comparison
valu
differ
laboratori
still
confus
antigenemia
test
semiquantit
fluoresc
assay
stain
circul
neutrophil
cmv
earli
antigen
use
assess
viremia
similar
nat
assay
use
follow
respons
treatment
assay
may
neg
presenc
activ
infect
especi
gi
neurolog
retin
cmv
consequ
histopatholog
diagnosi
remain
gold
standard
cmv
diagnosi
patient
consist
clinic
syndrom
neg
test
viremia
undergo
tissu
biopsi
delay
diagnosi
lower
sensit
neither
cultur
serolog
test
routin
use
cmv
diagnosi
cmv
associ
wors
outcom
kidney
transplant
recipi
riskbas
prevent
essenti
univers
prophylaxi
preemptiv
therapi
use
routin
univers
prophylaxi
involv
administr
antivir
risk
period
typic
defin
recipi
donor
cmv
serostatu
preemptiv
approach
use
quantit
assay
monitor
cmv
reactivationinfect
specifi
time
point
posttranspl
patient
evid
cmv
treat
antivir
advantag
disadvantag
strategi
prophylaxi
may
reduc
indirect
effect
allograft
reject
opportunist
infect
decreas
risk
infect
herpesvirus
cost
toxic
prolong
antivir
may
impedi
approach
preemptiv
strategi
may
reduc
cost
medic
medicationrel
advers
event
also
may
allow
effect
recoveri
host
immun
respons
coordin
care
cost
monitor
may
affect
feasibl
strategi
notabl
neither
approach
prevent
infect
resist
cmv
strain
current
guidelin
recommend
patient
highest
risk
cmv
receiv
antivir
prophylaxi
month
transplant
mani
center
opt
month
prophylaxi
base
studi
compar
month
group
cmv
drkidney
recipi
although
studi
support
use
acyclovir
valacyclovir
ganciclovir
major
center
current
use
valganciclovir
prophylaxi
given
eas
administr
improv
outcom
optim
dose
valganciclovir
prophylaxi
known
cmvseroposit
recipi
center
use
mg
daili
rather
recommend
dose
mg
least
one
center
suggest
lower
dose
may
appropri
cmv
drrecipi
regardless
valganciclovir
dose
determin
sole
basi
kidney
function
dose
reduct
made
medicationrel
toxic
includ
cytopenia
treatment
cmv
requir
administr
effect
antivir
sign
symptom
resolv
minimum
week
consid
standard
vast
major
cmv
isol
suscept
ganciclovir
iv
ganciclovir
dose
mgkg
everi
hour
dose
adjust
kidney
dysfunct
standard
regimen
mild
moder
diseas
valganciclovir
dose
mgkg
twice
daili
dose
adjust
kidney
dysfunct
consid
cmv
infect
often
consequ
overimmunosuppress
import
reassess
immunosuppress
regimen
consid
reduc
reduct
dose
suspens
mycophenol
azathioprin
commonli
consid
treatment
weekli
monitor
cmv
viral
load
recommend
determin
respons
treatment
week
log
decreas
viral
load
demonstr
viral
load
declin
week
patient
undergo
test
cmv
resist
use
genotyp
assay
risk
factor
resist
includ
cmv
drstatu
prolong
subtherapeut
exposur
ganciclovir
valganciclovir
ganciclovirresist
patient
may
treat
foscarnet
cidofovir
investig
agent
also
may
avail
foscarnet
cidofovir
nephrotox
close
monitor
kidney
function
electrolyt
therapi
critic
sever
concern
regard
treatment
cmv
case
especi
involv
gi
tract
viral
load
accur
reflect
extent
cmv
diseas
endoscop
evalu
perform
suspens
treatment
ensur
erad
infect
addit
recurr
diseas
occur
follow
complet
treatment
although
guidelin
suggest
may
role
either
secondari
prophylaxi
monitor
relaps
viral
load
monitor
trial
demonstr
either
approach
benefici
cmv
occur
usual
risk
period
prophylaxi
may
resum
complet
therapi
regardless
approach
chosen
risk
benefit
addit
prophylaxi
monitor
balanc
observ
standard
care
similar
cmv
ebv
member
herpesviru
famili
acquir
childhood
persontoperson
spread
primarili
via
saliva
vast
major
adult
kidney
recipi
seroposit
transplant
normal
host
ebv
first
infect
oropharyng
epitheli
cell
b
lymphocyt
establish
latenc
kidney
transplant
ebv
manifest
divers
way
commonli
reactiv
asymptomat
infecti
mononucleosislik
syndrom
ptld
also
occur
ebv
viremia
common
kidney
transplant
one
studi
show
kidney
recipi
monitor
regularli
experienc
ebv
viremia
median
time
viremia
day
viremia
common
ebvseroneg
recipi
seroposit
donor
kidney
associ
allograft
loss
increas
risk
opportunist
bacteri
infect
signific
complic
ebv
infect
ebvassoci
ptld
adult
kidney
transplant
recipi
lower
risk
compar
organ
transplant
estim
incid
major
risk
factor
ptld
includ
primari
infect
ebv
dr
net
state
immunosuppress
choic
immunosuppress
agent
use
induct
import
factor
subsequ
develop
ptld
antithymocyt
globulin
belatacept
implic
ebvseroneg
statu
contraind
use
belatacept
ptld
gener
divid
earli
ptld
occur
first
year
posttranspl
like
associ
primari
ebv
infect
polymorph
involv
allograftand
late
ptld
occur
first
year
usual
diseas
older
recipi
ebv
neg
monoclon
clinic
present
ebv
ptld
quit
variabl
caus
fever
undetermin
origin
also
present
mononucleosislik
syndrom
cytopenia
may
occur
involv
allograft
gi
tract
lung
liver
cn
describ
extranod
diseas
especi
common
late
ptld
constitut
b
symptom
sometim
present
quantit
nat
whole
blood
peripher
blood
mononuclear
cell
pbmc
plasma
serum
often
use
first
step
diagnosi
acut
ebv
ptld
number
issu
limit
util
assay
diagnost
purpos
import
recogn
specimen
select
major
effect
viral
load
measur
sinc
higher
viral
load
seen
whole
blood
cell
pbmc
furthermor
still
interlaboratori
variabl
relat
absenc
intern
refer
standard
make
difficult
compar
result
obtain
differ
laboratori
final
import
recogn
ptld
occur
absenc
viremia
presenc
viremia
may
occur
absenc
ptld
histopatholog
diagnosi
ultim
requir
make
diagnosi
world
health
organ
devis
criteria
stage
ptld
base
clinic
present
earli
stage
diseas
defin
benign
polyclon
prolifer
stage
ii
polymorph
diseas
stage
iii
monomorph
bor
tcell
lymphomaneoplasm
stage
iv
diseas
defin
classic
hodgkin
lymphoma
ptld
often
reflect
immunosuppress
state
key
compon
treatment
reduct
immunosuppress
may
result
signific
reduct
diseas
burden
individu
howev
increas
risk
reject
mani
patient
requir
addit
intervent
includ
rituximab
chemotherapi
surgeri
andor
radiat
oncolog
although
ptld
often
ebv
associ
role
antivir
multidisciplinari
approach
involv
transplant
physician
oncologist
infecti
diseas
specialist
recommend
optim
manag
patient
prevent
ptld
includ
multiti
approach
seroneg
recipi
belatacept
avoid
serial
viral
load
monitor
use
titrat
immunosuppress
especi
first
year
posttranspl
prevent
cmv
may
help
decreas
risk
cmv
identifi
potenti
cofactor
develop
ptld
rituximab
use
patient
persist
elev
ebv
viral
load
associ
increas
risk
infect
absenc
control
trial
current
recommend
recent
interest
use
cellbas
therapi
direct
specif
ebv
univers
avail
yet
approach
offer
promis
futur
therapeut
intervent
bk
viru
common
posttranspl
viral
infect
affect
predominantli
kidney
transplant
recipi
although
case
report
implic
caus
acut
kidney
injuri
solid
organ
recipi
first
identifi
urin
kidney
transplant
recipi
ureter
stenosi
viru
member
polyoma
famili
includ
jc
viru
saint
loui
polyomaviru
new
jersey
polyomaviru
least
six
differ
genotyp
identifi
differ
geograph
predomin
genotyp
common
worldwid
primer
util
pcr
detect
assay
base
strain
sever
common
risk
factor
bk
viremia
nephropathi
identifi
overal
degre
immunosuppress
probabl
import
factor
preval
bk
infect
increas
potent
immunosuppress
introduc
factor
augment
cumul
immunosuppress
burden
reject
episod
greater
hla
mismatch
also
increas
risk
older
age
male
sex
diabet
use
ureter
stent
also
implic
bk
risk
factor
grow
evid
suggest
infect
donor
deriv
absenc
prior
recipi
infect
may
increas
risk
nephropathi
one
studi
donor
recipi
bk
antibodi
titer
predict
bk
viremia
nephropathi
recipi
high
antibodi
titer
donor
kidney
increas
risk
bk
viremia
ci
p
corrobor
earlier
work
bohl
et
al
viral
load
monitor
diagnosi
prevent
bk
nephropathi
bk
antibodi
protect
effect
antivir
prophylaxi
yet
identifi
center
screen
prospect
bk
infect
measur
bk
viral
load
plasma
urin
sinc
major
bk
infect
detect
first
year
transplant
screen
concentr
earli
posttranspl
period
although
late
bk
infect
report
bk
infect
includ
investig
allograft
dysfunct
american
societi
transplant
ast
consensu
guidelin
recommend
screen
patient
bk
viremia
everi
month
first
year
posttranspl
major
transplant
center
screen
use
serum
bk
pcr
approach
mandat
urin
bk
pcr
remain
popular
altern
due
lack
univers
standard
assay
realtim
bk
pcr
signific
interlaboratori
variabl
assay
quantif
therefor
consist
laboratori
use
viral
load
monitor
import
result
inconsist
patient
clinic
cours
question
although
bk
viral
load
log
copiesml
presum
bk
nephropathi
diagnosi
made
kidney
biopsi
although
biopsi
may
chang
manag
provid
use
inform
regard
degre
inflamm
fibrosi
extens
risk
allograft
loss
bk
nephropathi
biopsi
mistaken
acut
cellular
reject
lymphocyt
infiltr
tubul
definit
diagnosi
made
demonstr
presenc
immunohistochem
stain
direct
larg
antigen
capsid
protein
stain
cornerston
bk
viremia
nephropathi
treatment
care
reduct
immunosuppress
varieti
approach
employ
achiev
includ
discontinu
antimetabolit
dose
reduct
cni
switch
cni
replac
anoth
agent
altogeth
vitro
data
suggest
sirolimu
cyclosporin
may
inhibitori
effect
bk
viral
replic
wherea
tacrolimu
permiss
suggest
reduct
tacrolimu
may
benefici
erad
bk
infect
shortand
longerterm
data
suggest
immunosuppress
reduct
result
bk
viral
clearanc
major
patient
neg
effect
allograft
patient
surviv
center
discontinu
antimetabolit
monitor
bk
viral
load
everi
week
thereaft
viral
load
respond
decreas
cni
aim
reduct
trough
level
anecdot
success
clear
bk
infect
patient
persist
viremia
despit
tacrolimu
trough
level
ngml
rang
switch
cyclosporin
aim
trough
level
mgdl
serum
creatinin
must
monitor
close
period
reduc
immunosuppress
although
retrospect
data
suggest
role
fluoroquinolon
antibiot
prevent
bk
infect
prospect
doubleblind
random
trial
levofloxacin
prophylaxi
prevent
bk
infect
kidney
transplant
recipi
fail
find
benefit
month
treatment
patient
enrol
studi
differ
incid
bk
viruria
vs
p
significantli
quinoloneresist
bacteri
infect
tendon
levofloxacin
group
case
seri
report
success
treat
bk
leflunomid
cidofovir
levofloxacin
iv
immunoglobulin
often
conjunct
immunosuppress
reduct
largescal
prospect
trial
advoc
use
agent
also
sever
report
lower
rate
bk
viremia
patient
maintain
sirolimu
increas
viral
clearanc
convers
mtor
inhibitor
howev
given
increas
risk
death
demonstr
sirolimu
use
kidney
transplant
popul
advoc
firstlin
treatment
approach
hepat
c
recent
data
nation
health
nutrit
examin
survey
nhane
indic
preval
hcv
infect
gener
us
popul
low
esrd
popul
enrich
hcv
preval
rang
depend
seri
dopp
dialysi
outcom
practic
pattern
studi
identifi
length
time
mainten
dialysi
one
import
predictor
hcv
infect
hcv
seropreval
greater
year
esrd
blood
transfus
prior
transplant
iv
drug
use
risk
hcv
acquisit
hcv
transmiss
dialysi
unit
well
describ
emphas
import
univers
precaut
without
need
patient
isol
recognit
risk
mainten
hemodialysi
patient
categor
ph
ird
recommend
kidney
diseas
initi
improv
global
outcom
kdigo
guidelin
screen
kidney
transplant
candid
hcv
infect
nat
hcv
rna
blood
prefer
antibodi
screen
highpreval
area
patient
unexplain
elev
hepat
transaminas
immunosuppress
popul
may
viral
loadposit
never
mount
antibodi
respons
antibodyneg
natposit
addit
nat
enabl
identif
patient
spontan
clear
infect
antibodyposit
natneg
earli
infect
patient
hcv
natposit
refer
hepatologist
assess
liver
diseas
sever
transplant
kidney
transplant
offer
surviv
benefit
hcvposit
patient
remain
mainten
dialysi
contemporari
case
seri
cardiovascular
diseas
rather
cirrhosi
predomin
caus
death
waitlist
although
earli
case
seri
suggest
posttranspl
patient
allograft
outcom
hcvposit
patient
similar
hcvneg
recipi
contemporari
data
metaanalys
indic
outcom
fact
wors
older
studi
identifi
cirrhosi
main
caus
death
hcvposit
transplant
recipi
newer
data
suggest
cardiovascular
diseas
diabet
signific
contributor
mortal
allograft
surviv
also
neg
affect
recipi
hcvposit
statu
metaanalysi
report
hazard
ratio
hr
ci
graft
loss
studi
consist
shown
neg
effect
hcv
infect
kidney
allograft
surviv
concern
immunosuppress
requir
kidney
transplant
could
acceler
liver
diseas
hcvposit
recipi
hcv
viral
load
shown
increas
transplant
histor
cirrhosi
main
caus
patient
mortal
howev
limit
case
seri
preand
posttranspl
liver
biopsi
avail
case
seri
report
patient
roth
et
al
stabl
improv
histolog
followup
biopsi
interv
worsen
liver
fibrosi
anoth
seri
franc
sequenti
posttranspl
biopsi
patient
show
similarli
benign
posttranspl
cours
despit
increas
viral
load
patient
studi
stabl
liver
fibrosi
repeat
biopsi
patient
develop
cirrhosi
year
followup
infect
may
one
sourc
increas
mortal
observ
hcvposit
transplant
recipi
although
report
identifi
sepsi
import
caus
death
hcvposit
patient
recent
prospect
studi
spain
observ
differ
overal
incid
infect
among
hcvposit
hcvneg
patient
howev
observ
signific
increas
bacteremia
hcvposit
recipi
hr
ci
p
long
wait
transplant
unit
state
overal
shortag
suitabl
donor
kidney
led
mani
center
explor
mean
expand
donor
pool
use
nonstandard
donor
hcv
infect
grow
opioid
abus
epidem
increas
hcv
infect
rate
certain
region
unit
state
lead
increas
overdos
death
donor
hcv
infect
histor
use
hcvposit
organ
restrict
recipi
genotyp
infect
donor
hcv
genotyp
avail
transplant
clinician
assum
hcvposit
deceas
donor
genotyp
infect
sinc
preval
genotyp
unit
state
howev
superinfect
hcv
genotyp
possibl
sinc
pangenotyp
ifnfre
directact
antivir
daa
agent
cure
hcv
exist
limit
genotyp
recipi
may
outdat
one
largest
publish
singl
seri
describ
use
hcvposit
donor
come
spain
moral
colleagu
report
outcom
hcvposit
recipi
hcvposit
kidney
compar
hcvposit
recipi
hcvneg
donor
patient
surviv
year
similar
dr
vs
r
p
allograft
surviv
diminish
allograft
surviv
dr
compar
dr
p
recent
propens
score
match
analysi
perform
use
unit
network
organ
share
uno
data
address
question
found
transplant
hcvposit
donor
associ
increas
risk
death
hr
ci
p
graft
loss
hr
ci
p
among
hcvposit
recipi
effect
explain
differ
acut
reject
ci
p
given
time
frame
studi
unknown
daa
erad
hcv
would
chang
outcom
use
hcvposit
donor
hcvposit
individu
associ
shorter
wait
time
transplant
year
less
averag
recipi
counsel
risk
benefit
associ
use
donor
whether
hcvposit
donor
may
safe
use
hcvneg
recipi
current
area
studi
potenti
treatment
option
hcv
expand
presum
donor
virem
much
less
like
transmit
hcv
via
transplant
consequ
increas
interest
use
donor
data
need
determin
safeti
hcvposit
donor
initi
kdigo
guidelin
era
daa
therapi
recommend
treatment
hcv
kidney
transplant
candid
recent
meant
pretranspl
treatment
ifnbas
regimen
modest
respons
rate
therapi
poor
toler
treatment
ifn
kidney
transplant
associ
unaccept
high
rate
acut
reject
graft
loss
sinc
rapid
expans
number
ifnfre
daa
regimen
approv
treat
hcv
infect
regimen
associ
hcv
cure
rate
excess
gener
popul
demonstr
efficaci
kidney
transplant
recipi
well
daa
regimen
select
kidney
transplant
recipi
complex
current
greatest
number
therapeut
option
exist
patient
genotyp
infect
area
rapidli
chang
american
associ
studi
liver
diseas
aasld
infecti
diseas
societi
america
idsa
guidelin
provid
current
treatment
recommend
continu
updat
new
inform
becom
avail
kidney
function
daaimmunosuppress
drugdrug
interact
must
taken
account
daa
regimen
select
sofosbuvircontain
regimen
approv
use
patient
glomerular
filtrat
rate
less
mlmin
regimen
contain
simeprevir
increas
cyclosporin
level
elbasvirgrazeprovir
coadminist
cyclosporin
increas
grazeprovir
level
addit
regimen
requir
ritonavir
boost
dasabuvirombitasvirparitaprevir
result
major
increas
cni
blood
level
requir
signific
cni
dose
adjust
regimen
gener
avoid
posttranspl
set
cni
level
shown
fluctuat
even
daa
treatment
complet
highlight
need
care
monitor
kidney
function
drug
level
therapi
prescrib
also
need
awar
issu
viral
resist
appropri
test
resist
mutat
genotyp
patient
depend
regimen
select
well
report
hepat
b
reactiv
hcv
therapi
treatment
hcv
kidney
transplant
recipi
manag
care
combin
effort
hepatologist
infecti
diseas
specialist
transplant
nephrologist
unlik
hcv
preval
hbv
us
esrd
popul
low
estim
around
like
due
effort
vaccin
chronic
kidney
diseas
ckd
patient
start
dialysi
improv
infect
control
dialysi
unit
widespread
use
erythropoietinstimul
agent
rather
transfus
manag
anemia
kidney
transplant
candid
screen
hbv
infect
time
transplant
evalu
measur
hepat
b
surfac
antigen
hbsag
hepat
b
surfac
antibodi
hbsab
core
antibodi
hbcab
addit
regular
screen
conduct
dialysi
unit
patient
hbsagposit
detect
hbv
dna
refer
hepatolog
evalu
treatment
patient
hbsabposit
immun
whether
vaccin
clear
infect
latter
presenc
hbcab
detect
patient
immun
vaccin
prefer
initi
renal
replac
therapi
initi
outcom
kidney
transplant
hepat
binfect
recipi
poor
tenyear
patient
surviv
allograft
surviv
cirrhosi
frequent
complic
develop
year
posttranspl
followup
hepatocellular
carcinoma
common
howev
introduct
effect
hbv
therapi
routin
clinic
practic
improv
outcom
significantli
studi
hbsagposit
recipi
transplant
patient
surviv
allograft
surviv
significantli
differ
contemporari
hbvneg
control
fivefold
increas
risk
hepat
decompens
among
hbvposit
recipi
observ
howev
complic
occur
patient
overal
transplant
candid
chronic
hbv
infect
screen
cirrhosi
well
coinfect
hcv
hepat
counsel
avoid
hepatotoxin
includ
alcohol
current
cure
hbv
infect
patient
hbsagposit
andor
dnaposit
receiv
lifelong
antivir
therapi
routin
screen
complic
chronic
infect
includ
cirrhosi
hepatocellular
carcinoma
individu
hbcabposit
may
risk
reactiv
hbv
intens
period
immunosuppress
especi
bcell
deplet
agent
rituximab
use
anticip
rituximab
treatment
patient
check
hepat
b
prophylact
antivir
consid
hbcabandor
hbsagposit
individu
improv
outcom
patient
due
multitud
antivir
agent
avail
treat
hbv
lamivudin
among
wide
use
recommend
longterm
prophylaxi
due
low
barrier
resist
tenofovir
difumar
highli
potent
high
barrier
resist
nephrotox
associ
bone
loss
make
unattract
choic
chronic
use
kidney
transplant
patient
tenofovir
alafenamid
newer
formul
effect
hbv
lower
risk
associ
kidney
impair
osteopenia
entecavir
also
highli
effect
high
barrier
resist
without
nephrotox
therefor
often
use
kidney
transplant
recipi
requir
chronic
hbv
therapi
hbvposit
kidney
explor
mean
increas
avail
donor
pool
guidelin
use
develop
work
group
american
societi
transplant
risk
transmiss
hbv
depend
sever
factor
includ
particular
organ
transplant
recipi
hbv
immun
hbv
prophylaxi
strategi
employ
hbsagposit
donor
use
least
frequent
repres
deceas
donor
use
hbsagposit
recipi
requir
lifelong
treatment
entecavir
tenofovir
regardless
due
recipi
hbv
statu
addit
hepat
b
immunoglobulin
hbig
administr
could
consid
hbsab
titer
low
hbsagposit
kidney
use
hbsabposit
recipi
without
antivir
prophylaxi
minim
transmiss
risk
use
hbsagposit
donor
hbvnaiv
unvaccin
patient
advis
hbcabposit
donor
use
hbcabposit
andor
hbsabposit
recipi
prophylaxi
requir
hepat
bnaiv
unvaccin
recipi
also
receiv
hbcabposit
kidney
sinc
risk
transmiss
low
guidelin
suggest
lamivudin
may
consid
year
posttranspl
prophylaxi
recipi
receiv
kidney
hbvposit
donor
posttranspl
monitor
hbv
dna
viral
load
surfac
antigen
core
antibodi
individu
without
prior
infect
regardless
immun
statu
hiv
infect
known
risk
factor
develop
ckd
esrd
widespread
adopt
potent
antiretrovir
therapi
arv
contribut
declin
esrd
among
white
hiv
infect
rate
esrd
still
disproportion
higher
among
affect
black
kidney
transplant
accept
ideal
therapi
esrd
even
among
hivposit
individu
hivposit
patient
diminish
access
wait
list
less
like
achiev
kidney
transplant
hivposit
patient
evalu
singl
transplant
center
achiev
waitlist
compar
hivneg
patient
time
period
studi
waitlist
outcom
hivposit
patient
demonstr
although
waitlist
mortal
similar
hivneg
patient
adjust
hazard
ratio
ahr
ci
p
hivposit
candid
less
like
receiv
deceas
donor
transplant
ahr
ci
p
significantli
less
like
achiev
live
donor
transplant
ahr
ci
p
howev
kidney
transplant
associ
surviv
benefit
compar
remain
waitlist
adjust
risk
ratio
arr
ci
p
hivposit
patient
observ
highrisk
patient
group
due
high
patient
mortal
high
rate
allograft
failur
hivposit
patient
transplant
prearv
era
hiv
consid
rel
contraind
transplant
howev
improv
hiv
patient
surviv
widespread
implement
potent
arv
therapi
rel
contraind
reconsid
numer
case
seri
report
promis
result
nation
institut
health
nih
fund
multicent
prospect
trial
assess
feasibl
kidney
transplant
hivposit
patient
studi
enrol
patient
center
across
unit
state
follow
year
patient
surviv
allograft
surviv
year
similar
outcom
older
kidney
recipi
report
scientif
registri
transplant
recipi
srtr
outcom
wors
hcvcoinfect
recipi
sinc
public
result
nih
trial
sever
group
examin
nation
experi
hivposit
transplant
use
registri
data
one
studi
compar
outcom
recipi
hiv
recipi
hivhcv
coinfect
uninfect
refer
group
hiv
monoinfect
patient
mortal
hr
ci
allograft
loss
hr
ci
statist
differ
increas
risk
death
hr
graft
loss
hr
ci
hivhcv
coinfect
patient
mate
kidney
analysi
control
donor
qualiti
found
similar
result
studi
match
hivposit
recipi
hivneg
control
interestingli
lock
et
al
demonstr
experi
hivposit
transplant
reflect
center
particip
nih
multicent
trial
affect
outcom
patient
surviv
ahr
p
allograft
surviv
ahr
p
era
effect
patient
transplant
better
outcom
transplant
earlier
despit
fact
hiv
infect
state
overal
immunosuppress
higher
expect
rate
acut
reject
consist
observ
nih
multicent
trial
incid
reject
first
year
compar
expect
scientif
registri
transplant
recipi
srtr
reject
rate
hivneg
kidney
transplant
recipi
similarli
high
incid
reject
report
multipl
subsequ
case
seri
unit
state
europ
excess
acut
reject
risk
may
entir
due
immun
dysregul
hiv
infect
drugdrug
interact
select
induct
mainten
immunosuppress
well
viral
suppress
like
also
play
role
recent
studi
demonstr
patient
undetect
viral
load
less
year
transplant
like
experi
acut
reject
kidney
transplant
analysi
srtr
databas
reveal
hivposit
patient
less
like
receiv
lymphocytedeplet
induct
therapi
hivneg
control
vs
use
antithymocyt
globulin
associ
lower
risk
reject
rr
ci
p
mainten
immunosuppress
also
import
studi
patient
mainten
sirolimu
higher
risk
reject
arr
ci
cni
data
singlecent
case
seri
suggest
tacrolimu
use
hivposit
recipi
associ
lower
acut
reject
risk
cyclosporin
p
drugdrug
interact
arv
cni
complex
proteas
inhibitor
pi
histor
main
compon
arv
regimen
potent
inhibitor
cytochrom
cyp
enzym
system
main
metabol
pathway
cni
pi
cni
coadminist
result
higher
cni
level
necessit
cni
dose
reduct
patient
pi
cyclosporin
mean
fourto
fivefold
lower
cyclosporin
dose
increas
dose
interv
wherea
patient
tacrolimu
pi
requir
dose
decreas
sevenfold
increas
dose
interv
nonnucleosid
revers
transcriptas
inhibitor
nnrti
gener
induc
enzym
activ
caus
subtherapeut
level
individu
effect
vari
nnrti
easili
overcom
increas
cni
dose
achiev
desir
trough
level
light
complex
interact
mani
transplant
profession
prefer
use
pifre
regimen
whenev
possibl
favor
regimen
base
integras
inhibitor
permit
tradit
cni
dose
shown
safe
effect
transplant
set
altern
one
could
consid
use
belatacept
ebv
seroposit
recipi
avoid
cnipi
interact
describ
sever
case
report
infect
common
complic
hivneg
transplant
special
concern
hivposit
recipi
nih
trial
patient
infecti
complic
requir
hospit
major
infect
bacteri
natur
common
site
involv
genitourinari
tract
respiratori
tract
bloodstream
author
note
infect
type
twice
common
among
recipi
receiv
antithymocyt
globulin
induct
recipi
develop
bk
nephropathi
similar
preval
observ
hivneg
transplant
popul
contemporari
studi
use
srtr
data
link
medicar
claim
fail
find
increas
risk
infect
associ
induct
immunosuppress
hivposit
kidney
transplant
recipi
rate
infect
overal
first
year
similar
among
hivposit
patient
receiv
induct
antithymocyt
globulin
receptor
antibodi
common
infect
nation
cohort
urinari
tract
importantli
patient
receiv
induct
either
type
spent
fewer
day
hospit
fewer
readmiss
overal
superior
deathcensor
graft
surviv
receiv
induct
immunosuppress
opportunist
infect
prophylaxi
hivposit
recipi
similar
approach
use
hivneg
patient
hivspecif
data
exist
suggest
need
aggress
prophylaxi
american
societi
transplant
infecti
diseas
guidelin
outlin
one
approach
author
suggest
lifelong
prophylaxi
pneumocysti
pneumonia
ideal
trimethoprimsulfamethoxazol
atovaquon
dapson
substitut
patient
sulfa
allergi
cmv
prophylaxi
also
recommend
atrisk
recipi
either
valganciclovir
ganciclovir
use
mani
center
dose
vs
mgd
durat
therapi
vs
month
mirror
use
hivneg
popul
although
fluconazol
use
select
center
nih
trial
antifung
prophylaxi
mani
center
prefer
nystatin
avoid
drugdrug
interact
cni
prophylaxi
infect
toxoplasmosi
cellsmm
trimethoprimsulfamethoxazol
mycobacterium
avium
complex
cellsmm
azithromycin
also
recommend
sinc
hivposit
transplant
recipi
robust
count
pretransplant
rare
prolong
period
sever
lymphocytopenia
posttranspl
rare
requir
nine
month
isoniazid
therapi
patient
previous
untreat
latent
mycobacterium
tb
strongli
advis
use
data
nationwid
inpati
sampl
hiv
research
network
uno
estim
potenti
hivposit
donor
unit
state
per
year
sourc
lack
necessari
inform
assess
donor
organ
qualiti
studi
hivposit
patient
die
hiv
care
philadelphia
granular
clinic
inform
abl
identifi
potenti
suitabl
hivposit
donor
year
median
kidney
donor
profil
index
kdpi
measur
organ
qualiti
indic
organ
would
consid
margin
kidney
use
hivposit
donor
unit
state
potenti
increas
access
transplant
hivposit
individu
extent
organ
contribut
donor
pool
remain
unknown
organ
qualiti
may
concern
multicent
trial
use
hivposit
donor
underway
provid
use
inform
guid
futur
use
hivposit
donor
kidney
transplant
patient
increas
risk
opportunist
infect
due
divers
fungal
pathogen
includ
candida
speci
aspergillu
cryptococcu
pneumocysti
us
nation
survey
fungal
infect
reveal
candida
infect
common
account
infect
cryptococcu
occur
aspergillu
survey
patient
endem
mycos
seen
pneumocysti
rel
uncommon
account
infect
kidney
recipi
risk
factor
clinic
present
vari
base
pathogen
prophylact
strategi
transnet
multicent
survey
candida
albican
common
candida
speci
found
transplant
bloodstream
infect
common
site
infect
methodolog
use
collect
case
transnet
mucocutan
infect
common
manifest
candida
captur
candida
also
associ
intraabdomin
infect
commonli
kidney
pancrea
recipi
uti
devicerel
infect
candiduria
pose
uniqu
situat
kidney
transplant
recipi
may
simpli
repres
colon
especi
women
import
differenti
infect
colon
guidelin
recommend
treatment
asymptomat
candiduria
import
recogn
symptomat
infect
fungu
ball
result
obstruct
uropathi
especi
recipi
poor
bladder
function
undergo
urinari
tract
manipul
treatment
indic
circumst
risk
factor
candida
infect
similar
found
gener
popul
includ
diabet
mellitu
renal
replac
therapi
broadspectrum
antibiot
use
parenter
nutrit
central
venou
cathet
neutropenia
kidney
pancrea
transplant
recipi
undergo
enter
drainag
increas
risk
candida
infect
due
surgic
procedur
overal
mortal
transplant
recipi
candida
infect
transnet
survey
mortal
highest
patient
infect
nonalbican
candida
speci
addit
risk
factor
mortal
kidney
recipi
includ
presenc
hepat
andor
renal
insuffici
congest
heart
failur
use
amphotericin
b
optim
treatment
candida
infect
depend
site
speci
import
remov
implic
devic
eg
iv
cathet
whenev
possibl
fungu
ball
may
requir
surgic
remov
choic
antifung
determin
base
speci
empir
treatment
echinocandin
consid
speci
identifi
howev
agent
penetr
well
urinari
tract
consequ
avoid
uti
azol
prefer
treatment
uti
vast
major
c
albican
speci
suscept
fluconazol
treatment
lesssuscept
nonalbican
speci
may
requir
treatment
echinocandin
voriconazol
amphotericin
b
lipid
formul
azol
use
import
consid
potenti
drug
interact
cni
mtor
inhibitor
dose
adjust
immunosuppress
agent
often
requir
time
initi
azol
therapi
multicent
epidemiolog
studi
fungal
infect
transplant
patient
transnet
identifi
cryptococcu
second
common
invas
fungal
infect
kidney
transplant
recipi
opportunist
infect
typic
occur
late
transplant
median
time
onset
day
posttranspl
common
manifest
cn
diseas
basilar
mening
pneumonia
risk
factor
diseas
includ
endstag
liver
diseas
lymphocyt
deplet
secondari
alemtuzumab
antithymocyt
globulin
given
late
onset
infect
environment
exposur
may
also
play
role
mortal
associ
infect
high
transnet
reveal
mortal
although
studi
estim
mortal
approxim
baselin
kidney
failur
risk
factor
mortal
prompt
recognit
treatment
cryptococc
infect
critic
patient
surviv
mani
patient
present
typic
sign
symptom
basilar
mening
includ
headach
visual
symptom
includ
diplopia
pulmonari
nodul
skin
nodul
liver
renal
rare
bone
joint
diseas
also
describ
predilect
cryptococcu
cn
involv
patient
extraneur
diseas
undergo
lumbar
punctur
exclud
mening
involv
lumbar
punctur
includ
measur
open
pressur
import
prognost
indic
well
glucos
protein
cell
count
fungal
cultur
cryptococc
antigen
serum
cryptococc
antigen
perform
neg
serum
antigen
exclud
possibl
cryptococc
diseas
lumbar
punctur
andor
tissu
biopsi
may
still
warrant
patient
suspect
infect
optim
treatment
infect
depend
site
diseas
ideal
includ
induct
phase
lipidbas
amphotericin
follow
fluconazol
patient
cn
sever
diseas
optim
durat
therapi
unknown
import
follow
patient
repeat
lumbar
punctur
imag
appropri
ensur
diseas
resolut
import
complic
cryptococc
infect
develop
immun
reconstitut
inflammatori
syndrom
iri
especi
associ
rapid
taper
immun
suppress
manifest
worsen
cryptococc
symptom
find
serial
lumbar
punctur
requir
presenc
iri
mening
decreas
intracrani
pressur
specif
treatment
complic
corticosteroid
benefici
anecdot
report
aspergillu
note
caus
invas
fungal
infect
kidney
recipi
transnet
studi
typic
seen
first
month
posttranspl
mortal
high
transnet
report
mortal
invas
aspergillosi
rate
similar
seen
larg
multicent
multin
studi
notabl
graft
loss
also
high
affect
patient
invas
aspergillu
major
infect
involv
lung
although
extrapulmonari
dissemin
infect
occur
risk
factor
develop
invas
pulmonari
aspergillu
multin
studi
includ
pretranspl
chronic
obstruct
pulmonari
diseas
seriou
posttranspl
infect
impair
allograft
function
addit
risk
factor
includ
hemodialysi
intensifi
immunosuppress
includ
prolong
high
dose
corticosteroid
diagnosi
requir
differenti
colon
infect
consequ
pulmonari
infect
requir
combin
imag
typic
comput
tomographi
respiratori
tract
microbiolog
sampl
extrapulmonari
site
often
requir
tissu
biopsi
patholog
cultur
galactomannan
obtain
serum
bronchoalveolar
lavag
use
adjunct
diagnosi
neg
serum
galactomannan
exclud
diagnosi
treatment
choic
voriconazol
although
signific
drug
interact
must
manag
especi
cni
mtor
inhibitor
addit
iv
formul
voriconazol
includ
cyclodextran
base
caus
hyperviscos
administ
individu
ckd
azol
includ
posaconazol
isavuconazol
echinocandin
lipid
formul
amphotericin
also
effect
unknown
whether
combin
therapi
improv
outcom
multin
studi
show
benefit
cohort
renal
transplant
recipi
pneumocysti
jirovecii
formerli
known
pneumocysti
carinii
uncommon
caus
pneumonia
kidney
transplant
recipi
account
fungal
infect
transnet
studi
low
incid
like
reflect
common
use
trimethoprim
sulfamethoxazol
earli
posttranspl
period
although
rel
uncommon
mortal
quit
high
increas
immunosuppress
especi
agent
reduc
absolut
count
high
dose
corticosteroid
cmv
reject
proxim
patient
p
jirovecii
pneumonia
pjp
recogn
risk
factor
pjp
radiograph
find
variabl
diagnosi
pjp
requir
sampl
respiratori
secret
typic
via
bronchoscopi
cytolog
pcr
often
provid
diagnosi
burden
organ
lower
seen
patient
hiv
infect
biopsi
may
requir
exclud
diagnosi
serum
beta
dglucan
often
elev
may
clue
diagnosi
treatment
choic
highdos
trimethoprim
sulfamethoxazol
coupl
taper
cours
higherdos
corticosteroid
given
potenti
poor
outcom
patient
pjp
import
provid
prophylaxi
atrisk
individu
commonli
month
trimethoprim
sulfamethoxazol
recommend
transplant
longer
cours
consid
patient
requir
higher
dose
immunosuppress
includ
treatment
reject
individu
cmv
also
increas
risk
pjp
center
reinstitut
pjp
prophylaxi
patient
develop
cmv
infect
altern
regimen
includ
atovaquon
dapson
patient
normal
level
consid
patient
allerg
trimethoprim
sulfamethoxazol
bacteri
infect
major
caus
morbid
mortal
transplant
surgic
site
infect
pneumonia
diabet
foot
infect
seen
common
infect
relat
urinari
tract
involv
site
may
anticip
base
time
transplant
surgic
site
infect
occur
first
month
pneumonia
occur
relat
hospit
acquisit
earli
typic
bacteri
pathogen
eg
streptococcu
pneumonia
legionella
speci
later
period
kidney
transplant
recipi
increas
risk
reactiv
tb
opportunist
bacteri
infect
includ
nocardia
speci
import
consid
divers
pathogen
evalu
patient
present
sign
symptom
infect
net
state
immunosuppress
latent
infect
new
environment
exposur
consid
develop
diagnost
plan
mani
case
invas
test
may
requir
confirm
diagnosi
uti
common
bacteri
infect
seen
kidney
transplant
recipi
preval
although
commonli
seen
earli
posttranspl
period
import
realiz
uti
occur
time
follow
transplant
especi
women
pyelonephr
bloodstream
infect
commonli
seen
one
survey
bloodstream
infect
kidney
transplant
attribut
uti
whether
uti
signific
effect
longterm
allograft
function
controversi
vari
definit
uti
variabl
find
base
time
infect
posttranspl
lack
uniform
measur
assess
kidney
function
use
clinic
studi
make
difficult
assess
overal
effect
regardless
infect
associ
increas
mortal
least
acut
impair
kidney
function
possibl
longterm
allograft
damag
risk
factor
uti
vari
time
transplant
includ
femal
sex
diabet
mellitu
ureter
stent
urinari
tract
catheter
urinari
tract
abnorm
includ
reflux
immunosuppress
antithymocyt
globulin
mycophenol
reduc
allograft
function
en
bloc
doubl
kidney
transplant
deceas
donor
acut
reject
may
difficult
recogn
uti
kidney
transplant
recipi
usual
symptom
may
present
given
disrupt
usual
neural
pathway
allograft
tender
often
seen
standard
definit
uti
reflect
use
nontranspl
recipi
includ
demonstr
pyuria
bacteriuria
e
coli
remain
common
organ
caus
uti
import
perform
suscept
test
urinari
tract
isol
sinc
increasingli
frequent
report
multidrugresist
pathogen
ultrasound
comput
tomographi
imag
may
confirm
diagnosi
pyelonephr
reveal
structur
abnorm
increas
risk
uti
treatment
infect
base
suspect
site
infect
someth
difficult
given
atyp
present
infect
shorter
durat
ie
day
recommend
lower
tract
infect
pyelonephr
treat
day
antibacteri
relapsedrecurr
infect
organ
warrant
prolong
treatment
week
choic
antimicrobi
consid
potenti
resist
sever
ill
drug
interact
especi
immunosuppress
agent
iv
therapi
initi
sever
infect
patient
frequent
persist
uti
assess
structur
abnorm
surgic
intervent
consid
appropri
signific
area
controversi
manag
asymptomat
bacteriuria
recent
prospect
trial
treatment
asymptomat
bacteriuria
commenc
month
posttranspl
fail
show
benefit
treat
asymptomat
bacteriuria
current
guidelin
recommend
treat
patient
especi
given
potenti
risk
advers
event
includ
increas
antibacteri
resist
c
difficil
optim
manag
patient
recurr
infect
unknown
correct
structur
function
abnorm
perform
postmenopaus
women
may
benefit
vagin
estrogen
urinari
acidif
also
employ
chronic
prolong
antimicrobi
reserv
recipi
complic
cours
sinc
signific
potenti
advers
effect
antibiot
success
transplant
like
candid
care
evalu
infect
risk
transplant
includ
assess
home
work
environ
includ
prior
live
arrang
person
contact
pet
hobbi
potenti
tb
endem
diseas
coccidioid
strongyloid
reactiv
transplant
import
evalu
patient
diseas
may
acquir
earlier
due
resid
area
infect
endem
especi
import
need
evalu
candid
tb
infect
may
reactiv
transplant
diagnosi
treatment
complic
immunosuppress
therapi
includ
take
thorough
histori
obtain
chest
radiographi
perform
either
intraderm
skin
test
use
ppd
igra
given
reduc
sensit
test
patient
ckd
import
assess
individu
risk
infect
take
care
histori
review
chest
radiographi
sign
prior
infect
patient
evid
latent
tb
complet
prior
prophylact
therapi
treat
month
isoniazid
either
transplant
shortercours
rifampicin
contain
regimen
consid
pretranspl
set
signific
drug
interact
prevent
use
one
especi
import
intervent
pretranspl
set
review
updat
vaccin
statu
given
potenti
reduc
immunogen
efficaci
vaccin
administ
transplant
increas
risk
transplant
recipi
vaccineprevent
infect
especi
import
recommend
vaccin
includ
tabl
hepat
b
vaccin
especi
import
patient
list
transplant
sinc
increas
risk
transmiss
dialysi
center
patient
immun
may
safe
transplant
kidney
donor
histori
hepat
b
increas
risk
new
hepat
b
infect
patient
ckd
receiv
doubl
dose
recombin
vaccin
hepat
b
surfac
antibodi
level
measur
follow
complet
vaccin
seri
histor
concern
regard
increas
risk
reject
influenza
vaccin
due
develop
low
level
de
novo
antihla
antibodi
immun
howev
linkag
vaccin
reject
demonstr
studi
examin
medicar
claim
data
first
year
kidney
transplant
demonstr
influenza
vaccin
associ
reduc
allograft
loss
death
ideal
vaccin
updat
transplant
howev
nonliv
viru
vaccin
may
safe
administ
transplant
possibl
may
advis
delay
posttranspl
immun
month
improv
vaccin
respons
patient
transplant
immedi
influenza
season
vaccin
may
given
sooner
transplant
transplant
recipi
may
suboptim
vaccin
respons
import
vaccin
household
contact
well
ckd
transplant
associ
reduc
vaccin
respons
individu
receiv
conjug
pneumococc
vaccin
follow
pneumococc
polysaccharid
capsul
vaccin
maxim
vaccin
respons
vaccin
schedul
updat
annual
import
review
ensur
appropri
immun
administ
although
kidney
transplant
recipi
increas
risk
infect
care
consider
specif
infect
risk
implement
prevent
measur
earli
recognit
infect
may
mitig
risk
given
everchang
natur
transplant
ongo
consider
prevent
strategi
includ
antimicrobi
immun
environment
assess
util
direct
diagnost
strategi
prompt
recognit
infect
essenti
optim
posttranspl
outcom
